Document:

<PAGE>

                                                                   EXHIBIT 10.18

                                 AMENDMENT NO. 5

                                       TO

                        THE DEVELOPMENT AND MANUFACTURING
                               SERVICES AGREEMENT

                              DATED 08 JANUARY 2004

                                     BETWEEN

                               LONZA BIOLOGICS PLC

                                       AND

                          TRUBION PHARMACEUTICALS, INC.

                                                          CONFIDENTIAL TREATMENT

<PAGE>

THIS AMENDMENT No. 5 ("Fifth Amendment") is made the 18th day of February, 2005

BETWEEN

LONZA BIOLOGICS PLC of 228 Bath Road, Slough, Berkshire SL1 4DX, England
(hereinafter referred to as "LB"), and

TRUBION PHARMACEUTICALS, INC., of 2401 4th Avenue, Suite 1050, Seattle, WA
98121, USA (hereinafter referred to as the "Customer")

WHEREAS

A.   LB and the Customer entered into a development and manufacturing services
     agreement ("the Agreement") dated 08 January 2004, pursuant to which LB
     agreed to provide Services to the Customer, and,

B.   The Customer now wishes LB to perform additional services under the
     Agreement, and,

C.   LB is willing to perform such additional services on the terms set out in
     the Agreement, and

D.   The parties wish to amend the Agreement in accordance with Clause 13.5
     thereto.

NOW THEREFORE IT IS HEREBY AGREED as follows:

1.   Two new stages, Stages 23 and 24, shall be added to Schedule 2 of the
     Agreement to read as follows:

STAGE 23 ***

     23.1 OBJECTIVES

          ***

     23.2 ACTIVITIES

          ***

     23.3 DELIVERABLES

          23.3.1 Copies of all Process specific documentation prepared in
activity 23.2.1 which has not already been supplied to the Customer

     23.4 TIMESCALE

     Stage 23 will be scheduled in to the Services in such a way that it is not
rate limiting and shall be complete when LB and the Customer have approved the
documentation and when a copy of the approved final bulk Product specification
has been sent to the Customer.

                                                          CONFIDENTIAL TREATMENT

<PAGE>

     It is estimated that Stage 23 will be complete approximately *** from the
commencement of Stage 23.

STAGE 24 ***

     24.1 OBJECTIVES

          ***

     24.2 ACTIVITIES

          ***

     24.3 DELIVERABLES

          24.3.1 A Certificate of Analysis for the Batch of bulk Product
manufactured.

          24.3.2 If requested by Customer, a copy of the completed manufacturing
batch record.

          24.3.3 The manufactured Product, including samples and in-Process
samples to be supplied to Customer as agreed by the parties.

          NOTE: ***.

     24.4 TIMESCALE

          Stage 24 shall be complete upon issue to the Customer of the
Certificate of Analysis for the Batch of Product manufactured.

          It is estimated that the Certificate of Analysis will be issued
approximately *** from commencement of this Stage (estimated out of freeze ***).
If the Customer requests in writing, the Product can be shipped in quarantine
prior to release. It is estimated that this shipment could occur *** from
commencement of this Stage.

                                                          CONFIDENTIAL TREATMENT

                                       -2-

<PAGE>

2. Schedule 3 to the Agreement shall be amended to include provision for payment
for the above mentioned additional Service, as set out below hereto. Invoices
for these additional Services shall be issued, and Customer payments shall be
made, in U.S. dollars:

     1.   Price

     ***

     2.   Payment

     For Stage 23

          *** upon commencement of Stage 23.

          *** upon completion of Stage 23.

     For Stage 24

          *** upon commencement of the batch

          *** upon issue of the Certificate of analysis for the Batch.

3. *** as Permitted Subcontractor. The Agreement is amended to provide that LB
shall cause ***, in its capacity as a permitted subcontractor to LB under the
Agreement, to perform the Services described in Stages 23 and 24 of the
Agreement, to the extent necessary or useful to LB in LB's performance of the
services under the Agreement, and to provide all other assistance necessary or
useful to LB in LB's performance of the Services, including all assistance
required in order to implement the Process at ***, and the Customer consents to
the foregoing. In connection with the foregoing, LB shall cause *** to comply
with the terms of the Agreement, and such subcontracting shall not relieve LB of
and LB shall remain primarily liable for the performance of LB's obligations
under the Agreement.

4. Authority; Conflicts. Each party represents and warrants that (a) it has the
corporate power and authority and the legal right to enter into this Fifth
Amendment and to perform its obligations hereunder and under the Agreement (as
amended by this Fifth Amendment), and (b) it is not a party to any agreement
that does not permit or that prohibits it from fulfilling its obligations under
this Fifth Amendment or under the Agreement (as amended by this Fifth
Amendment), and each party covenants that it shall not enter into any agreement
that would not permit or would prohibit it from performing its obligations
hereunder and under the Agreement, including without limitation the Services
described in this Fifth Amendment. Furthermore, LB represents and warrants that,
to the best of its knowledge, after reasonable inquiry (a) *** has the legal
right to perform the Services described in Stages 23 and 24 of the Agreement,
and (b) *** is not a party to any agreement that does not permit or that
prohibits it from performing the Services described in Stages 23 and 24 of the
Agreement.

5. Miscellaneous.

     5.1 Any capitalised term used but not defined in this Fifth Amendment shall
have the meaning given in the Agreement. In the event of a conflict between the
terms of this Fifth Amendment and the Agreement, the terms of this Fifth
Amendment shall control.

                                                          CONFIDENTIAL TREATMENT

                                       -3-

<PAGE>

     5.2 This Fifth Amendment may be executed in counterparts, each of which
shall be deemed an original and all of which, taken together, shall constitute
one and the same agreement. This Fifth Amendment shall be effective upon full
execution by facsimile or original.

     Save as herein provided all other terms and conditions of the Agreement
shall remain in full force and effect.

     AS WITNESS the hands of the duly authorised representatives of the parties
hereto the day and year first above written.

Signed for and on behalf of
LONZA BIOLOGICS PLC                     /s/ Rene Imwinkleried
                                        ----------------------------------------
                                        Director
                                        Title

Signed for and on behalf of
TRUBION PHARMACEUTICALS INC.            /s/ Peter A. Thompson
                                        ----------------------------------------
                                        President & CEO
                                        Title

                                                          CONFIDENTIAL TREATMENT

                                       -4-<PAGE>

                                                                   EXHIBIT 10.19

                                 AMENDMENT No. 6

                                       to

                        THE DEVELOPMENT AND MANUFACTURING
                               SERVICES AGREEMENT

                              Dated 08 January 2004

                                     Between

                               LONZA BIOLOGICS PLC

                                       and

                          TRUBION PHARMACEUTICALS, INC.

                                                          CONFIDENTIAL TREATMENT

<PAGE>

THIS AMENDMENT No. 6 ("Sixth Amendment") is made the 28th day of April 2005
BETWEEN

LONZA BIOLOGICS PLC of 228 Bath Road, Slough, Berkshire SL1 4DX, England
(hereinafter referred to as "LB"), and

TRUBION PHARMACEUTICALS, INC., of 2401 4th Avenue, Suite 1050, Seattle, WA
98121, USA (herein after referred to as the "Customer")

WHEREAS

A.   LB and the Customer entered into a development and manufacturing services
     agreement ("the Agreement") dated 08 January 2004, pursuant to which LB
     agreed to provide Services to the Customer, and,

B.   The Customer now wishes LB to perform additional services under the
     Agreement, and,

C.   LB is willing to perform such additional services on the terms set out in
     the Agreement, and

D.   The parties wish to amend the Agreement in accordance with Clause 13.5
     thereto.

NOW THEREFORE IT IS HEREBY AGREED as follows:

     1. TWO NEW STAGES, STAGES 25 AND 26, SHALL BE ADDED TO SCHEDULE 2 OF THE
AGREEMENT TO READ AS FOLLOWS:

     "STAGE 25 ***

     BACKGROUND

     ***

     25.1 OBJECTIVES

          ***.

     25.2 ACTIVITIES

          ***

     25.3 DELIVERABLES

          25.3.1 A copy of the report of activities as prepared in activity
          25.2.11.

     25.4 TIMESCALE

     Stage 25 can commence upon signature of this Amendment and it is estimated
that Stage 25 will be complete approximately *** from commencement.

                                                          CONFIDENTIAL TREATMENT

<PAGE>

     STAGE 26 ***

     BACKGROUND

     ***

     26.1 OBJECTIVES

     ***

     26.2 ACTIVITIES

     ***

     26.3 DELIVERABLES

          26.3.1 A copy of the sampling plan prepared in activity 26.2.1.

          26.3.2 *** obtained in activity 26.2.12.

          26.3.3 Samples from the development study as agreed in activity 26.2.1
          and 26.2.14.

          26.3.4 A copy of the report of activities as prepared in activity
          26.2.15.

     26.4 TIMESCALE

     Stage 26 can commence upon signature of this Amendment and it is estimated
that Stage 26 will be complete approximately *** from commencement."

     SCHEDULE 3 TO THE AGREEMENT SHALL BE AMENDED TO INCLUDE PROVISION FOR
PAYMENT FOR THE ABOVE MENTIONED ADDITIONAL SERVICES, AS SET OUT BELOW HERETO.
INVOICES FOR THESE ADDITIONAL SERVICES SHALL BE ISSUED, AND CUSTOMER PAYMENTS
SHALL BE MADE, IN ***:

     "1.  PRICE

          ***

     2.   PAYMENT

     FOR STAGE 25

     *** upon commencement of Stage 25.

     *** upon completion of Stage 25.

     FOR STAGE 26

     *** upon commencement of Stage 26.

                                                          CONFIDENTIAL TREATMENT

                                       -2-

<PAGE>

     *** upon completion of Stage 26."

     SAVE AS HEREIN PROVIDED ALL OTHER TERMS AND CONDITIONS OF THE AGREEMENT
SHALL REMAIN IN FULL FORCE AND EFFECT.

     AS WITNESS the hands of the duly authorised representatives of the parties
hereto the day and year first above written.

Signed for and on behalf of
LONZA BIOLOGICS PLC                     /s/ Rene Imwinkleried
                                        ----------------------------------------
                                        Director
                                        Title

Signed for and on behalf of
TUBION PHARMACEUTICALS, INC.            /s/ Kendall M. Mohler
                                        ----------------------------------------
                                        Senior VP Research & Development
                                        TITLE

                                                          CONFIDENTIAL TREATMENT

                                      -3-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00110-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00110-of-00352.parquet"}]]